13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
69 檔
9.7%
During the Q3 2024 filing period, Vestal Point Capital, LP (CIK: 0001974915) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $4.3B across 69 reported positions.
During Q3 2024, Vestal Point Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 8.86% | +0.62% | NEW | |
| 2 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 7.60% | — | -40.00% | |
| 3 | CYTK | Cytokinetics Inc | Stock-Healthcare | 6.01% | -0.55% | EXIT | |
| 4 | NARIUSD | Inari Medical Inc | Stock-Other | 4.85% | — | +342.86% | |
| 5 | ACLXGBX | Arcellx Inc | Stock-Other | 4.27% | — | — | |
| 6 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.83% | — | +105.36% | |
| 7 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.51% | -1.04% | EXIT | |
| 8 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 3.34% | — | +23.08% | |
| 9 | ✓ | Immatics NV | Stock-Other | 3.24% | -0.24% | +36.36% | |
| 10 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.16% | — | -58.33% | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.83% | -2.40% | EXIT | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.76% | -0.68% | EXIT | |
| 13 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.64% | — | +100.00% | |
| 14 | SVRA | Savara Inc | Stock-Other | 2.60% | -0.01% | +24.65% | |
| 15 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.56% | -0.43% | EXIT | |
| 16 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.46% | -0.05% | +57.14% | |
| 17 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.13% | +2.41% | — | |
| 18 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.99% | — | — | |
| 19 | BHVN | Biohaven Ltd. | Stock-Other | 1.89% | — | — | |
| 20 | QURE | uniQure N.V. | Stock-Other | 1.78% | +0.85% | — | |
| 21 | JANX | Janux Therapeutics Inc | Stock-Other | 1.67% | — | -33.10% | |
| 22 | BDTX | Black Diamond Therapeutics I | Stock-Other | 1.66% | — | +139.45% | |
| 23 | SLDB | Solid Biosciences Inc | Stock-Other | 1.48% | -0.51% | +5.07% | |
| 24 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.38% | — | — | |
| 25 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.27% | — | — | |
| 26 | LQDA | Liquidia CORP | Stock-Other | 1.14% | — | -18.03% | |
| 27 | A | Agilent Technologies Inc | Stock-Healthcare | 1.13% | — | — | |
| 28 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.98% | -0.62% | -50.00% | |
| 29 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 0.93% | — | — | |
| 30 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.82% | +0.62% | — | |
| 31 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.82% | — | -34.17% | |
| 32 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.79% | — | — | |
| 33 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.79% | — | -41.43% | |
| 34 | APLT | Applied Therapeutics Inc | Stock-Other | 0.74% | — | -78.91% | |
| 35 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.72% | +1.74% | -15.00% | |
| 36 | SNY | Sanofi-adr | Stock-Healthcare | 0.66% | +0.10% | — | |
| 37 | BRKR | Bruker CORP | Stock-Healthcare | 0.65% | — | — | |
| 38 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.61% | -2.59% | EXIT | |
| 39 | ZYME | Zymeworks Inc | Stock-Other | 0.59% | — | +39.77% | |
| 40 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.58% | -0.25% | +1.19% | |
| 41 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.57% | +1.15% | — | |
| 42 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.56% | -0.82% | +4.84% | |
| 43 | BDX | Becton Dickinson And Co | Stock-Healthcare | 0.55% | — | — | |
| 44 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.48% | +0.36% | — | |
| 45 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.46% | — | — | |
| 46 | FATE | Fate Therapeutics Inc | Stock-Other | 0.45% | — | -15.75% | |
| 47 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.39% | — | — | |
| 48 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.39% | -0.07% | EXIT | |
| 49 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.37% | +0.94% | +4.49% | |
| 50 | GERN | Geron CORP | Stock-Other | 0.36% | -0.11% | EXIT |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 69 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, JAZZ, CYTK) accounted for 9.7% of total reported equity market value during Q3 2024.
During Q3 2024, Vestal Point Capital, LP's top holdings by market value included INSM (8.9%)、JAZZ (7.6%)、CYTK (6.0%). The largest single position, INSM, represented 8.9% of total portfolio value.
In Q3 2024, Vestal Point Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.